6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A GGGGCC 24+ hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), fatal neurodegenerative diseases with no cure or approved treatments that substantially slow disease progression or extend survival. Mechanistic underpinnings of neuronal death include C9ORF72 haploinsufficiency, sequestration of RNA-binding proteins in the nucleus, and production of dipeptide repeat proteins. Here, we used an adeno-associated viral vector system to deliver CRISPR/Cas9 gene-editing machineries to effectuate the removal of the HRE from the C9ORF72 genomic locus. We demonstrate successful excision of the HRE in primary cortical neurons and brains of three mouse models containing the expansion (500–600 repeats) as well as in patient-derived iPSC motor neurons and brain organoids (450 repeats). This resulted in a reduction of RNA foci, poly-dipeptides and haploinsufficiency, major hallmarks of C9-ALS/FTD, making this a promising therapeutic approach to these diseases.

          Abstract

          A hexanucleotide repeat expansion in C9ORF72 is the most common genetic cause of ALS and FTD. Here, the authors demonstrate CRISPR/Cas9 excision of the expansion results in a rescue of disease mechanisms in vivo and in vitro.

          Related collections

          Most cited references80

          • Record: found
          • Abstract: found
          • Article: not found

          A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

          Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems provide bacteria and archaea with adaptive immunity against viruses and plasmids by using CRISPR RNAs (crRNAs) to guide the silencing of invading nucleic acids. We show here that in a subset of these systems, the mature crRNA that is base-paired to trans-activating crRNA (tracrRNA) forms a two-RNA structure that directs the CRISPR-associated protein Cas9 to introduce double-stranded (ds) breaks in target DNA. At sites complementary to the crRNA-guide sequence, the Cas9 HNH nuclease domain cleaves the complementary strand, whereas the Cas9 RuvC-like domain cleaves the noncomplementary strand. The dual-tracrRNA:crRNA, when engineered as a single RNA chimera, also directs sequence-specific Cas9 dsDNA cleavage. Our study reveals a family of endonucleases that use dual-RNAs for site-specific DNA cleavage and highlights the potential to exploit the system for RNA-programmable genome editing.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Multiplex genome engineering using CRISPR/Cas systems.

            Functional elucidation of causal genetic variants and elements requires precise genome editing technologies. The type II prokaryotic CRISPR (clustered regularly interspaced short palindromic repeats)/Cas adaptive immune system has been shown to facilitate RNA-guided site-specific DNA cleavage. We engineered two different type II CRISPR/Cas systems and demonstrate that Cas9 nucleases can be directed by short RNAs to induce precise cleavage at endogenous genomic loci in human and mouse cells. Cas9 can also be converted into a nicking enzyme to facilitate homology-directed repair with minimal mutagenic activity. Lastly, multiple guide sequences can be encoded into a single CRISPR array to enable simultaneous editing of several sites within the mammalian genome, demonstrating easy programmability and wide applicability of the RNA-guided nuclease technology.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

              Several families have been reported with autosomal-dominant frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), genetically linked to chromosome 9p21. Here, we report an expansion of a noncoding GGGGCC hexanucleotide repeat in the gene C9ORF72 that is strongly associated with disease in a large FTD/ALS kindred, previously reported to be conclusively linked to chromosome 9p. This same repeat expansion was identified in the majority of our families with a combined FTD/ALS phenotype and TDP-43-based pathology. Analysis of extended clinical series found the C9ORF72 repeat expansion to be the most common genetic abnormality in both familial FTD (11.7%) and familial ALS (23.5%). The repeat expansion leads to the loss of one alternatively spliced C9ORF72 transcript and to formation of nuclear RNA foci, suggesting multiple disease mechanisms. Our findings indicate that repeat expansion in C9ORF72 is a major cause of both FTD and ALS. Copyright © 2011 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                zzeier@med.miami.edu
                Christian.mueller4@sanofi.com
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                21 October 2022
                21 October 2022
                2022
                : 13
                : 6286
                Affiliations
                [1 ]GRID grid.168645.8, ISNI 0000 0001 0742 0364, Horae Gene Therapy Center, , University of Massachusetts Medical School, ; Worcester, MA 01605 USA
                [2 ]GRID grid.168645.8, ISNI 0000 0001 0742 0364, Department of Neurology, , University of Massachusetts Medical School, ; Worcester, MA 01605 USA
                [3 ]GRID grid.168645.8, ISNI 0000 0001 0742 0364, RNA Therapeutics Institute and Program in Molecular Medicine, , University of Massachusetts Medical School, ; Worcester, MA 01605 USA
                [4 ]GRID grid.417467.7, ISNI 0000 0004 0443 9942, Department of Neuroscience, Mayo Clinic, ; Jacksonville, FL 32224 USA
                [5 ]GRID grid.26790.3a, ISNI 0000 0004 1936 8606, Department of Psychiatry & Behavioral Sciences, Center for Therapeutic Innovation, , University of Miami Miller School of Medicine, ; Miami, FL 33136 USA
                [6 ]GRID grid.66875.3a, ISNI 0000 0004 0459 167X, Department of Quantitative Health Sciences. Mayo Clinic, ; Rochester, MN 55905 USA
                [7 ]GRID grid.26790.3a, ISNI 0000 0004 1936 8606, Department of Neurology, , University of Miami Miller School of Medicine, ; Miami, FL 33136 USA
                [8 ]GRID grid.168645.8, ISNI 0000 0001 0742 0364, Department of Molecular, Cell and Cancer Biology, , University of Massachusetts Medical School, ; Worcester, MA 01605 USA
                Author information
                http://orcid.org/0000-0003-0151-2983
                http://orcid.org/0000-0003-0059-2248
                http://orcid.org/0000-0002-8724-5427
                http://orcid.org/0000-0001-7552-099X
                http://orcid.org/0000-0002-7335-2627
                http://orcid.org/0000-0001-8578-0891
                http://orcid.org/0000-0002-0260-6773
                http://orcid.org/0000-0001-7703-4872
                http://orcid.org/0000-0001-8873-5404
                http://orcid.org/0000-0002-0881-0310
                http://orcid.org/0000-0001-6062-1528
                http://orcid.org/0000-0003-0623-8610
                http://orcid.org/0000-0003-3589-8749
                Article
                33332
                10.1038/s41467-022-33332-7
                9587249
                36271076
                693b4d62-3184-4c9d-a60f-554b809ff18b
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 8 February 2021
                : 13 September 2022
                Funding
                Funded by: FundRef https://doi.org/10.13039/100000065, U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS);
                Award ID: NS088689
                Award ID: NS088689
                Award Recipient :
                Funded by: U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Uncategorized
                crispr-cas9 genome editing,amyotrophic lateral sclerosis
                Uncategorized
                crispr-cas9 genome editing, amyotrophic lateral sclerosis

                Comments

                Comment on this article